Free Trial
NASDAQ:OPRX

OptimizeRx Q2 2025 Earnings Report

OptimizeRx logo
$13.26 -0.74 (-5.25%)
As of 02:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OptimizeRx EPS Results

Actual EPS
N/A
Consensus EPS
$0.03
Beat/Miss
N/A
One Year Ago EPS
N/A

OptimizeRx Revenue Results

Actual Revenue
N/A
Expected Revenue
$22.27 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

OptimizeRx Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

OptimizeRx Earnings Headlines

Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
See More OptimizeRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OptimizeRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptimizeRx and other key companies, straight to your email.

About OptimizeRx

OptimizeRx (NASDAQ:OPRX), Inc. (NASDAQ: OPRX) is a digital health company that provides cloud-based engagement solutions for the pharmaceutical, healthcare and life sciences industries. The company’s platform integrates with electronic health record (EHR) systems to deliver targeted communications, patient support and adherence messaging at the point of care. By leveraging real-time prescribing data, OptimizeRx enables manufacturers and healthcare organizations to reach prescribers, pharmacists, payers and patients with patient assistance programs, savings opportunities and clinical information when and where it matters most.

Since its founding in 2008, OptimizeRx has developed a suite of offerings that includes digital prescription coupon delivery, patient co-pay assistance, prior authorization support and clinical decision support tools. Its solutions are embedded into leading EHR applications and pharmacy management systems, facilitating seamless, bi-directional data flow and enabling secure, compliant interaction across the care continuum. Key products include Formulary Adherence, which promotes on-formulary prescribing; Free4Me™, which automates discount card distribution; and MultiCare™, which supports complex patient assistance and affordability programs.

OptimizeRx primarily serves the United States market, connecting to more than 400,000 healthcare providers and over 65,000 pharmacies nationwide. Over the years, the company has expanded its network through strategic partnerships with major EHR vendors and pharmacy benefit managers, broadening its footprint across specialty, retail and acute care settings. Historical milestones include the launch of its first EHR-integrated messaging service in 2010 and the introduction of compliance-focused offerings following the ACA, which enhanced patient affordability and streamlined prior authorization workflows.

Guided by a leadership team with extensive experience in digital health, life sciences and regulatory compliance, OptimizeRx continues to innovate its platform to address evolving market needs. The company is headed by a seasoned executive group that combines expertise in technology development, healthcare delivery and commercial operations, positioning OptimizeRx to support manufacturers and providers in improving patient access, reducing administrative burden and driving better clinical outcomes.

View OptimizeRx Profile

More Earnings Resources from MarketBeat